• news.cision.com/
  • CS MEDICA A/S/
  • CS MEDICA's Subsidiary Signs Agreement to Target the German Market, Leveraging Expertise of Nimbus Health, a Dr. Reddy's Laboratories company.
English

CS MEDICA's Subsidiary Signs Agreement to Target the German Market, Leveraging Expertise of Nimbus Health, a Dr. Reddy's Laboratories company.

Report this content

CANNORDIC Collaborates with Nimbus Health GmbH, a Specialist in Medical Cannabis, to Enhance Patient Care in Germany

CS MEDICA, a pioneer in MedTech specializing in pain management, autoimmune diseases, and stress-related disorders with its compliant CBD-infused medical treatments, is pleased to announce a strategic partnership between its subsidiary CANNORDIC A/S and Nimbus Health GmbH, a German provider specializing in prescription-based, medical cannabis treatments.

This partnership will enable the integration of pain management focused medical device products from CANNORDIC into Nimbus Health's branded portfolio, expanding access to compliant, CBD-infused therapies. Targeting the German market is pivotal for CS MEDICA as it represents the largest market for self-care approaches, where CBD usage is mature, and consumer knowledge is exceptionally high, leading to increasing demand for evidence-based products.

Lone Henriksen, CEO of CS MEDICA, states, "This partnership represents a significant advancement in our mission to enhance access to scientifically validated, CBD-infused products. Incorporating our proven formulations under Nimbus's brand will address the growing patient demand for effective and reliable medical cannabinoid therapies."

Lone continues: "We began our discussions over a year ago. Our engagement with a partner as Nimbus Health, a Dr. Reddy's Laboratories company, that prioritizes patient safety, compliance, and accessibility has enriched our processes and commercial strategies."

Ozan Temizkan, Managing Director of Nimbus Health, states: "As a company, we are committed to accelerating access to cannabinoid-based medicines for German patients. In this effort, we constantly look for complementary products to expand our offering to meet patients' needs, especially in pain management. That is why Cannordic's CBD-infused pain patch will be an important product in our portfolio."

The selected product will be rebranded under Nimbus Health's label and will be available online under the healthcare line RHYZAX® from January 2025 in Germany, with a potential market expansion later.

 


For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

 

About Nimbus Health GmbH, part of Dr. Reddy's Laboratories, known for its purpose of providing access to affordable and innovative medicines and healthcare solutions, is committed to ensuring the continuous supply of high-quality medical cannabis products to patients.  


CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally. The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes. 
 

Tags:

germany Compliance cannabis medical device pain management MDR CS MEDICA marketexpansion CANNORDIC Nimbus Health Dr Reddys Laboratories

Subscribe

Documents & Links

Quick facts

This partnership will enable the integration of pain management focused medical device products from CANNORDIC into Nimbus Health's branded portfolio, expanding access to compliant, CBD-infused therapies.
Tweet this
The selected product will be rebranded under Nimbus Health's label and will be available online under the healthcare line RHYZAX® from January 2025 in Germany, with a potential market expansion later.
Tweet this

Quotes

As a company, we are committed to accelerating access to cannabinoid-based medicines for German patients. In this effort, we constantly look for complementary products to expand our offering to meet patients' needs, especially in pain management. That is why Cannordic's CBD-infused pain patch will be an important product in our portfolio.
Ozan Temizkan, Managing Director of Nimbus Health
This partnership represents a significant advancement in our mission to enhance access to scientifically validated, CBD-infused products. Incorporating our proven formulations under Nimbus's brand will address the growing patient demand for effective and reliable medical cannabinoid therapies.
Lone Henriksen, CEO of CS MEDICA
We began our discussions over a year ago. Our engagement with a partner as Nimbus Health, a Dr. Reddy's Laboratories company, that prioritizes patient safety, compliance, and accessibility has enriched our processes and commercial strategies.
Lone Henriksen, CEO of CS MEDICA